Risk factors

Biohaven (BHVN) risk factors

Item 1A of every Biohaven Ltd. 10-K on file, and what changed from one year to the next.

Open BHVN in Gloomberb →
  • FY2025 10-K risk factors

    61 risks, 6 new, 7 reworded since the prior year. Biohaven secured a $250 million note purchase agreement with Oberland Capital Management.

    Filed Mar 02, 2026
  • FY2024 10-K risk factors

    55 risks. Biohaven faces substantial operating losses, with a net loss of $846.4 million in 2024 and no product revenues to date. The company relies heavily on third-party suppliers, clinical trial outcomes, and patent protection for candidates like troriluzole and taldefgrobep alfa.

    Filed Mar 03, 2025